01:38:02 Paul Hutchinson: Please type any questions you have for the speaker into the Chat box 01:38:09 Alejandro Arevalo: What is your approach in making the distinction between “atypical” CLL and “leukaemic” mantle cell lymphoma based on flow cytometric parameters alone ? I believe both may have reduced to absent CD23 (particularly for atypical CLL) and expression of CD200 can be seen in some cases of leukaemic MCL? Thank you. 01:40:20 indhira/hospital sultanah aminah jb: how to differentiate Marginal zone lymphoma and lymphoplasmacytoid lymphoma 01:42:41 Pek Kuen Liew: Do u use a cut off 20% of aberrant plasma cells in peripheral blood for diagnosing plasma cell leukaemia or it can be lower depending on morphology as well? 01:42:49 Paul Hutchinson: Where do the plasma cells go in flow cytometry? Problem with sample preparation (eg RBC lysis)? 01:43:18 shafini: what are markers should be included for MRD detection plasma cell myeloma 01:45:18 sammycheang: what we will get if the plasma cell tube is stained with surface kappa/lambda markers? always negative? 01:47:49 Alia Suzana: Do u use BCL2 in FCM? If yes what is the internal control? 01:51:14 Paul Hutchinson: We are having a discussion after Prof Brent's last talk. If you have any questions that haven't been answered so far we can discuss them then. 02:03:43 Liu yixian: Based on the ontogeny of T cells, there is possible of - T Lymphoblastic Lymphoma/leukaemia from flow cytometry with Cd34/tdt negative? 02:04:30 marneabdullah: Why do the plasma cells reduced in the tube with cykappa/cylambda as compared to other tubes without the cytoplasmic markers? How to overcome the loss of plasma cells in the tube with kappa/lambda? 02:11:05 Mardziah Mohamad: Can the diagnosis of T-LGL be made just based on the loss of CD4 to CD8 ratio without aberrant loss of any T-cell markers? 02:16:40 Adam Seegmiller: Answering some of these questions via chat... 02:17:36 Adam Seegmiller: Loss of plasma cells by flow cytometry is likely due to some combination of poor aspiration from the bone marrow, hemodilution, and preferential loss of abnormal plasma cells in process, as they appear to be more fragile than other normal cells. 02:17:54 Paul Hutchinson: Thanks Adam. Good idea 02:19:00 Adam Seegmiller: A recent consensus document recommends the following markers for plasma cell myeloma MRD: CD19, CD38, CD138, CD45, CD56, CD27, CD81, CD117, and kappa/lambda. 02:21:32 Adam Seegmiller: https://pubmed.ncbi.nlm.nih.gov/25907102/ 02:22:31 Adam Seegmiller: Plasma cells should be negative for surface kappa/lambda, both normal and neoplastic. Sometimes you can see dim expression in B-cell lymphomas with plasmacytic differentiation. 02:23:03 indhira/hospital sultanah aminah jb: T PLL 02:23:03 Liu yixian: Do TCL1 02:35:07 Liu yixian: Anaplastic T cell Lymphoma in leukaemia phase is rare, is it common you perform cd30 in your flow panels? 02:43:09 ICA Committee comp 1: Dear participants, here is the link for Beckman Coulter Quiz: 02:44:12 ICA Committee comp 1: https://forms.office.com/r/zHhRWYUewp 03:00:34 Paul Hutchinson: https://forms.office.com/r/zHhRWYUewp 03:09:41 Hubertus_ICA Committee: Hello. The following is a link for BD presentation feedback survey consisting of 6 questions only. Your filling and submitting it will be much appreciated. Thank you. https://forms.office.com/Pages/ResponsePage.aspx?id=fObDlC2eAEimt2Ndl4ghZS5msnOJidJFrvgKRptew2hUMTkzSE1ENlJZNVNEOUhISDNDUVo4Rk82RC4u 03:43:55 Liu yixian: It appears that MRD flow in AML is very complex due to heterogenous AML subset, would you recommend some standardised panels? 03:46:49 Nabeelah/ HPP Malaysia: re B-ALL MRD, 1. if we get residual blasts but below detection sensitivity (eg 0.01% residual blast, and detection sensitivity is 0.02% ), how do we report this? is it safe to say this is MRD neg? 2. if the residual blast % is different btw mrd tube 1 and mrd tube 2, which one do we report? 03:48:56 PekKuen Liew: in validation of MRD panels, how many samples sets of serial dilution experiments are needed to validate the assay? 03:56:37 PekKuen Liew: What will be the gating strategy to gate monocytes population accurately in AML monocytic in MRD? Ssc vs 45 or other monocytic markers specifically? 03:56:52 Liu yixian: For B-All, are cd58 and cd81 important markers important in both diagnostic and later on in MRD monitoring? 03:58:31 razanhayati: 1) in a place where MRD detection sensitivity is not established, can we safely commit as MRD positive, especially in a case where borderline value we get. ie 0.0112? 04:00:20 shafini: What are the minimum markers should be included for MRD detection for BALL 04:01:14 razanhayati: 2) in a case where, CD34 heterogenous at diagnosis, can we still safely use CD34 during the assessment of MRD? and if we still using the marker (CD34) for assessment, if it's negative, can we safely commit as MRD negative? 04:03:01 razanhayati: 3) How do we assess mrd in T-ALL if the patient does not have any abberancy? and also especially in a case where we don't have cycd3 and cd3 in the same panel? especially In a place where only 6 colur flow available, what is your advice panel for assessment mrd in t-all? 04:17:42 Paul Hutchinson: https://www.cytometryunderground.com/Jakarta_Flow_2021.html 04:18:48 Paul Hutchinson: https://www.surveymonkey.com/r/JMVMSNT 04:22:29 Paul Hutchinson: https://www.surveymonkey.com/r/5JY6LM9